International Journal of Toxicology · 2011 · 36 citations · 29 references
Veterinary MedicinePharmacologyToxicologyMechanisms Of ToxicityPharmaceutical ToxicologyToxicologic PathologyBiomarkers Of Liver InjuryHepatic NecrosisHepatic ToxicityHepatotoxicity MechanismsLiver DiseaseLiver Function TestsBiomarkersBiomarkers Of Liver ToxicityHepatic BiomarkersHepatocellular Injury BiomarkersHepatocyte NecrosisHistopathological BiomarkersSafety BiomarkersSerum Alanine Aminotransferase
This article addresses the issue of miscorrelation between hepatic injury biomarkers and histopathological findings in the drug development context. Our studies indicate that the use of toxicogenomics can aid in the drug development decision-making process associated with such miscorrelated data. BLZ945 was developed as a Colony-Stimulating Factor 1 Receptor (CSF-1R) inhibitor. Treatment of BLZ945 in rats and monkeys increased serum alanine aminotransferase (ALT) and aspartate transaminase (AST). However, liver hypertrophy was the only histopathological liver finding in rats, and there was no change in the livers of monkeys. Longer treatment of BLZ945 in rats for 6 weeks caused up to 6-fold elevation of ALT, yet hepatocyte necrosis was not detected microscopically. Toxicogenomic profiling of liver samples demonstrated that the genes associated with early response to liver injury, apoptosis/necrosis, inflammation, oxidative stress, and metabolic enzymes were upregulated. Studies are ongoing to evaluate the mechanisms underlying BL945-induced ALT and AST elevations.
29
Gene Expression Analysis Reveals Chemical-Specific Profiles
Hisham K. Hamadeh · Toxicological Sciences · 2002 · 430 citations · Full text
Pharmacy, Pharmacology, Toxicology +16
Serum alanine aminotransferase in skeletal muscle diseases†
Rahul A. Nathwani, Shireen Pais, Telfer B. Reynolds et al. · Hepatology · 2005 · 400 citations